Prof. Xiao Li 李肖
Chief Physician, Professor
Department of Interventional Therapy, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: TIPS procedures for portal hypertension and complications; interventional treatment for benign and malignant tumors and vascular diseases; ablation and particle implantation for malignant tumors.
Dr. Li is Chief of the Department of Interventional Therapy at Cancer Hospital, Chinese Academy of Medical Sciences. A doctoral supervisor at Peking Union Medical College and Sichuan University, Dr. Li serves as chief PI for a national key R&D program. Research focuses on tumors and vascular diseases. Dr. Li has published over 70 SCI papers in journals including Gut, Radiology, JVIR, and CVIR.
Professional roles
- Vice Chair, Interventional Diagnosis and Treatment Committee, Radiology Branch, Chinese Medical Association
- Standing Committee Member, Interventional Physicians Branch, Chinese Medical Doctor Association
- Chair, Portal Hypertension Bleeding Expert Committee, Chinese Research Hospital Association
- Vice President, Interventional Specialist Physicians Branch, Beijing Medical Doctor Association
Name order: in Chinese the family name comes first (Li Xiao). Papers usually list the name as Xiao Li or Li X.
Selected publications
127 papers on PubMed matched by name and affiliation; 53 as first or senior author since 2016. Most recent first- or senior-author papers:
- Liver Cancer, 2026 (senior author): Atezolizumab plus Bevacizumab with or without Transarterial Chemoembolization as First-Line Treatment for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma: A Nationwide Multicenter Retrospective Study. PubMed 42924094
- Hepatol Int, 2026 (senior author): Enhancing post-TIPS hepatic encephalopathy risk stratification: a hybrid TabPFN model leveraging radiomics, deep transfer learning features, and MELD score. PubMed 41264208
- Cancer Med, 2026 (senior author): The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy for Mismatch Repair Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer Liver Metastases (CRLM). PubMed 41796273
- Am J Cancer Res, 2025 (senior author): Lower MMP12 expression is likely to contribute to better effect of postoperative adjuvant transarterial chemoembolization via reducing MEK/ERK signaling activity in patients with hepatocellular carcinoma. PubMed 41244123
- World J Hepatol, 2025 (senior author): Optimal guiding methods for transjugular intrahepatic portosystemic shunt creation: Characteristics of intravascular ultrasound vs other techniques. PubMed 40901582
- World J Clin Oncol, 2025 (senior author): Lifestyle factors in hepatocellular carcinoma: From pathogenesis to prognosis. PubMed 40741187
- 3D Print Med, 2025 (first author): Enhancing skull base tumor management: the combination of 3D printing technology and endoscopic surgical techniques. PubMed 40504428
- Quant Imaging Med Surg, 2025 (senior author): A comparative study of 4-hook anchor device with methylene blue for preoperative pulmonary nodule localization. PubMed 39839047
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion